DT
BBIO icon

Diversified Trust’s BridgeBio Pharma BBIO Stock Holding History

Diversified Trust’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,971
Closed -$3.27M – 1128
2026
Q1 		$3.27M Buy
43,971
+4,770
+12% +$346K 0.06% 172
2025
Q4 		$3M Sell
39,201
-1,385
-3% -$90.9K 0.06% 182
2025
Q3 		$2.11M Buy
40,586
+1,981
+5% +$96.6K 0.04% 247
2025
Q2 		$1.67M Buy
38,605
+3,739
+11% +$136K 0.04% 268
2025
Q1 		$1.21M Buy
34,866
+7,039
+25% +$237K 0.03% 312
2024
Q4 		$764K Sell
27,827
-8,945
-24% -$231K 0.02% 456
2024
Q3 		$936K Buy
36,772
+1,059
+3% +$27.8K 0.02% 398
2024
Q2 		$905K Buy
35,713
+8,011
+29% +$219K 0.03% 358
2024
Q1 		$857K Buy
27,702
+10,066
+57% +$342K 0.03% 355
2023
Q4 		$712K Buy
17,636
+525
+3% +$15.8K 0.02% 392
2023
Q3 		$451K Buy
17,111
+411
+2% +$11.7K 0.02% 494
2023
Q2 		$287K Buy
+16,700
New +$251K 0.01% 646

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Diversified Trust's BBIO Position: Q2 2026 in Review

Diversified Trust sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 43,971 shares — an estimated $3.27M sold.

Diversified Trust first reported a position in BBIO in Q2 2023 and held it in 12 quarters. The position peaked at $3.27M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Diversified Trust reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Diversified Trust sold 43,971 BridgeBio Pharma shares in Q2 2026, an estimated $3.27M.
  • Diversified Trust first reported a position in BridgeBio Pharma in Q2 2023 and held it in 12 quarters.
  • Diversified Trust's BridgeBio Pharma position peaked at $3.27M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Diversified Trust's 13F filing for Q2 2026, filed 17 Jul 2026.